RASMUS ROJKJAER. Founder & CEO
Dr. Rasmus Rojkjaer drove the build-up of major biotech competencies, capacities and blockbuster portfolios at Novo Nordisk, Mylan and Alvotech, and has been at the forefront of the biotech movement since its inception. He has led over 30 biopharmaceutical product development efforts, and established partnerships and operations across the globe.
NAWEL BAILEY. Founder & President
Nawel Bailey is a leading expert in pharmaceutical competitiveness and policies to improve patient access to life-saving medicines. She has represented the generic and biosimilar industry before global regulators, as well as in international trade negotiations. As part of senior management teams in major public and private companies, she has been dedicated to ensuring broad access to quality affordable medicines for patients around the world.
PETER KALINKA. Chief Manufacturing Officer
Dr. Kalinka has held executive positions with Sandoz and Apotex, directing the development of multiple key biologic products, including Europe’s first ever approved biosimilar. He brings a unique experience in biomanufacturing and a global perspective from the very start of the industry.
MORT JORGENSEN. CCO & CFO (Acting)
Mort Jorgensen holds over 20+ years experience in finance, capital formation and investment banking, coupled with a decade-long experience founding and leading an alternative pharmacy drug distribution network. He brings a unique expertise of pharmaceutical sales & distribution in North America to the Haber Team’s global biopharm strategy.